Press Releases Investor Overview News Press Releases Media Events and Presentations EVENTS AND PRESENTATIONS SCIENTIFIC PUBLICATIONS AND PRESENTATIONS Analyst Coverage SEC Filings Stock Information Stock Quote & Chart Historical Price Lookup Investment Calculator Corporate Governance Governance Overview Management Board of Directors Committee Composition Information Request Investor Overview News Press Releases Media Events and Presentations EVENTS AND PRESENTATIONS SCIENTIFIC PUBLICATIONS AND PRESENTATIONS Analyst Coverage SEC Filings Stock Information Stock Quote & Chart Historical Price Lookup Investment Calculator Corporate Governance Governance Overview Management Board of Directors Committee Composition Information Request Year None2026202520242023202220212020 December 3, 2025 Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients December 1, 2025 Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients on Wednesday, December 3, 2025 November 19, 2025 Protara Therapeutics Announces Positive Interim Results Demonstrating Robust Responses in the Ongoing Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations November 18, 2025 Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations on Wednesday, November 19, 2025 November 17, 2025 Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the 26th Annual Meeting of the Society of Urologic Oncology November 10, 2025 Protara Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update November 4, 2025 Protara Therapeutics Named a 2026 Best Places to Work Winner by BioSpace October 1, 2025 Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 2, 2025 Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 27, 2025 Protara Therapeutics to Participate in Upcoming Investor Conferences August 11, 2025 Protara Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update August 1, 2025 Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Pagination First page « Previous page ‹ Page 1 Current page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page › Last page » Displaying 13 - 24 of 132 Print Print Email Alerts Email Alerts RSS Feeds RSS Feeds Email Page Email Page
Year None2026202520242023202220212020 December 3, 2025 Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients December 1, 2025 Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients on Wednesday, December 3, 2025 November 19, 2025 Protara Therapeutics Announces Positive Interim Results Demonstrating Robust Responses in the Ongoing Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations November 18, 2025 Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations on Wednesday, November 19, 2025 November 17, 2025 Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the 26th Annual Meeting of the Society of Urologic Oncology November 10, 2025 Protara Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update November 4, 2025 Protara Therapeutics Named a 2026 Best Places to Work Winner by BioSpace October 1, 2025 Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 2, 2025 Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 27, 2025 Protara Therapeutics to Participate in Upcoming Investor Conferences August 11, 2025 Protara Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update August 1, 2025 Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Pagination First page « Previous page ‹ Page 1 Current page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page › Last page » Displaying 13 - 24 of 132
December 3, 2025 Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients
December 1, 2025 Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients on Wednesday, December 3, 2025
November 19, 2025 Protara Therapeutics Announces Positive Interim Results Demonstrating Robust Responses in the Ongoing Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations
November 18, 2025 Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations on Wednesday, November 19, 2025
November 17, 2025 Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the 26th Annual Meeting of the Society of Urologic Oncology
November 10, 2025 Protara Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update
October 1, 2025 Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 2, 2025 Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 11, 2025 Protara Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update
August 1, 2025 Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
